ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE Drug Patent Profile

Which patents cover Abacavir Sulfate, Lamivudine And Zidovudine, and what generic alternatives are available?

Abacavir Sulfate, Lamivudine And Zidovudine is a drug marketed by Lupin and is included in one NDA.

The generic ingredient in ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE is abacavir sulfate; lamivudine; zidovudine. There is one drug master file entry for this compound. Additional details are available on the abacavir sulfate; lamivudine; zidovudine profile page.

Summary for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
DailyMed Link:	ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE at DailyMed

Recent Clinical Trials for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gilead Sciences	Phase 3
Harvard School of Public Health (HSPH)	Phase 2
Harvard School of Public Health	Phase 2

See all ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE clinical trials

Pharmacology for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Drug Class	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Mechanism of Action	Cytochrome P450 1A1 Inhibitors Nucleoside Reverse Transcriptase Inhibitors

US Patents and Regulatory Information for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Lupin	ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE	abacavir sulfate; lamivudine; zidovudine	TABLET;ORAL	202912-001	Dec 5, 2013		DISCN	No	No

Abacavir Sulfate, Lamivudine and Zidovudine Market Dynamics, Patent Status and Financial Trajectory

Last updated: August 22, 2026

Abacavir sulfate, lamivudine and zidovudine is the fixed-dose HIV antiretroviral combination marketed as Trizivir. The product has low commercial relevance compared with newer integrase inhibitor regimens because of dated efficacy, high pill burden, mitochondrial toxicity concerns, resistance limitations and extensive generic competition. Its patent-based exclusivity has ended in major markets, and current revenue exposure is limited and largely unreported on a standalone basis.

What is abacavir sulfate, lamivudine and zidovudine?

Abacavir sulfate, lamivudine and zidovudine combines three nucleoside reverse transcriptase inhibitors:

Component	Drug class	Primary role
Abacavir sulfate	NRTI	Inhibits HIV reverse transcriptase
Lamivudine	NRTI	Inhibits HIV reverse transcriptase
Zidovudine	NRTI	Inhibits HIV reverse transcriptase

The U.S. product is Trizivir, marketed by ViiV Healthcare. The FDA approved Trizivir in November 2000 for treatment of HIV-1 infection in adults and adolescents weighing at least 40 kilograms. The product was intended to simplify triple-NRTI therapy by consolidating three active ingredients into one tablet taken twice daily.[1]

The regimen is no longer a preferred initial treatment option. Current HIV guidelines favor combinations built around integrase strand transfer inhibitors, such as dolutegravir or bictegravir, with two NRTIs. The U.S. Department of Health and Human Services does not recommend abacavir-containing regimens for most patients when alternatives are available, particularly because of the need for HLA-B*5701 screening and cardiovascular-risk considerations.[2]

What is the FDA regulatory status of Trizivir?

Trizivir remains an FDA-approved prescription drug, but it has limited strategic relevance in modern HIV treatment.

Regulatory item	Status
U.S. brand	Trizivir
Active ingredients	Abacavir sulfate, lamivudine and zidovudine
FDA approval	November 2000
Dosage form	Oral film-coated tablet
Dosing	One tablet twice daily
Indication	HIV-1 infection
Pediatric status	Patients weighing at least 40 kg
Current treatment role	Alternative or specialized use, not preferred first-line therapy
Key safety restrictions	Abacavir hypersensitivity, lactic acidosis, severe hepatomegaly with steatosis, hematologic toxicity and mitochondrial toxicity

The label requires testing for the HLA-B*5701 allele before starting abacavir. Patients who test positive have a materially higher risk of potentially fatal abacavir hypersensitivity and should not receive abacavir-containing products.[1]

The combination also inherits zidovudine-related adverse effects, including anemia and neutropenia. This creates a less favorable tolerability profile than newer two-drug or three-drug regimens.

When does abacavir, lamivudine and zidovudine lose exclusivity?

The product’s principal U.S. patent protections have expired. Trizivir no longer has meaningful composition-of-matter or combination-product exclusivity capable of blocking ordinary generic competition.

Patent and exclusivity timeline

Event	Approximate timing	Commercial effect
Zidovudine approved	1987	Established the first component market
Lamivudine approved	1995	Expanded the NRTI franchise
Abacavir approved	1998	Added a newer NRTI with HLA-B*5701 risk
Trizivir approved	2000	Created the fixed-dose triple-NRTI product
Early NRTI patents expire	2005-2011	Opened individual active ingredients to generic competition
Trizivir commercial decline accelerates	2010s	Integrase-based combinations displace triple-NRTI therapy
Current status	Post-exclusivity	Generic and multisource competition

The Orange Book historically listed patents associated with Trizivir and its active ingredients, but those protections are expired or no longer commercially blocking. FDA Orange Book listings should be distinguished from enforceable, unexpired market exclusivity. A listed patent does not by itself establish that a product has current practical protection.[3]

Abacavir’s U.S. patent estate included early compound and use patents associated with the development of Ziagen and related products. Lamivudine and zidovudine had earlier expiration dates. The relevant practical conclusion for Trizivir is that no remaining U.S. patent barrier supports a premium branded market.

What patents protect abacavir sulfate, lamivudine and zidovudine?

The original patent estate covered separate active ingredients, pharmaceutical compositions, treatment methods and, in some cases, combinations. The principal commercial protections were:

Patent category	Protected subject matter	Current effect
Abacavir compound patents	Abacavir and related chemical matter	Expired
Lamivudine compound patents	Lamivudine and stereochemical forms	Expired
Zidovudine compound patents	Zidovudine and nucleoside analog chemistry	Expired
Combination patents	Co-formulated abacavir, lamivudine and zidovudine	Expired or nonblocking
Method-of-use patents	HIV treatment and dosing methods	Expired
Formulation patents	Tablet composition and manufacturing	Expired or commercially weak
Pediatric or dosing exclusivity	Regulatory population protections	Expired

The product’s patent strength is therefore low. Any residual intellectual-property value would more likely arise from manufacturing know-how, regulatory files, supply arrangements or market access contracts than from enforceable exclusivity.

How strong is the patent estate?

Factor	Assessment
Composition-of-matter protection	None of practical commercial significance
Combination-product protection	Expired
Method-of-use protection	Expired
Formulation protection	Weak and expired in major markets
Patent litigation leverage	Low
Generic blocking ability	None in the United States
Biosimilar relevance	None
Manufacturing complexity	Moderate, but not a durable barrier

The drug is a small-molecule product, so biosimilar rules do not apply. Generic manufacturers can pursue abbreviated new drug applications rather than biosimilar applications.

Which companies are challenging Trizivir, and what generic entry risks exist?

Generic competition is the dominant market force. The active ingredients are widely available individually and in other combinations. Generic manufacturers can also market the fixed-dose combination if they satisfy FDA requirements for pharmaceutical equivalence, bioequivalence, chemistry, manufacturing and controls.

Potential or historical competitors include:

• Cipla
• Hetero
• Aurobindo Pharma
• Mylan, now part of Viatris
• Teva Pharmaceutical Industries
• Sandoz
• Aspen Pharmacare
• Emcure
• Matrix Laboratories
• Other regional HIV suppliers operating through public-health tenders

The competitive threat does not depend solely on an ANDA for the branded combination. Physicians and public-health systems can substitute separate generic tablets or other fixed-dose antiretroviral combinations. That substitution weakens the commercial value of the Trizivir brand even where the exact three-in-one generic has limited distribution.

What is the Paragraph IV challenge risk?

Paragraph IV risk is low as a forward-looking event because the principal patents associated with Trizivir have expired. A generic applicant would not need to build a commercial strategy around invalidating a live patent estate. If an applicant filed an ANDA with a Paragraph IV certification against an historical listing, the litigation exposure would depend on whether any listed patent remained unexpired and enforceable at the filing date.

The main launch risks are regulatory and commercial:

1. Demonstrating bioequivalence for the fixed-dose tablet.
2. Securing a reliable supply of all three active ingredients.
3. Managing zidovudine-related manufacturing and quality requirements.
4. Obtaining sufficient tender volume to justify registration and inventory.
5. Competing against inexpensive separate-component regimens.

What formulations are protected by Trizivir patents?

Trizivir is an immediate-release oral tablet containing fixed amounts of the three active ingredients. Its formulation value is limited because the product does not use a complex delivery system, depot technology, liposome, biologic platform or specialized release mechanism.

The principal formulation characteristics are:

Formulation attribute	Trizivir profile
Route	Oral
Release type	Immediate release
Dosing frequency	Twice daily
Dosage form	Film-coated tablet
Delivery technology	Conventional solid oral dosage form
Device dependence	None
Reformulation opportunity	Limited

The combination may reduce pill count relative to taking three separate NRTIs, but it does not match the once-daily convenience of newer HIV products. The twice-daily schedule is a commercial disadvantage in adherence-sensitive markets.

How does Trizivir compare with competing HIV drugs?

Trizivir has been displaced by both newer branded products and lower-cost generic combinations.

Product or regimen	Core components	Market position versus Trizivir
Triumeq	Abacavir, dolutegravir and lamivudine	More effective modern abacavir-based option; once daily
Dovato	Dolutegravir and lamivudine	Two-drug regimen with lower pill burden
Biktarvy	Bictegravir, emtricitabine and tenofovir alafenamide	Preferred modern single-tablet regimen
Genvoya	Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide	Older integrase-based single-tablet option
Generic TLD	Tenofovir, lamivudine and dolutegravir	Major public-health and tender competitor
Separate generic NRTIs	Individual components	Low-cost substitution option

Clinical and commercial comparison

Metric	Trizivir	Modern integrase-based regimens
Dosing	Twice daily	Usually once daily
Genetic barrier to resistance	Lower	Generally higher
HLA-B*5701 testing	Required	Not required unless abacavir is used
Hematologic toxicity	Zidovudine-related risk	Generally lower
Cardiovascular concern	Abacavir-related concern	Regimen dependent
Generic availability	Broad	Increasing, but varies by product
Payer preference	Low	Higher for preferred regimens
Brand pricing power	Minimal	Limited to products with active exclusivity

Trizivir can remain relevant where treatment history, renal considerations, formulary rules or procurement constraints narrow the available options. Those cases are unlikely to support meaningful growth.

What is the financial trajectory of abacavir, lamivudine and zidovudine?

The financial trajectory is mature-to-declining. Public company reports generally do not disclose Trizivir revenue as a separate line item. ViiV and its parent companies report broader HIV portfolios, making product-level revenue estimates difficult to verify from filings.[4]

Revenue trajectory

Period	Commercial condition	Financial implication
2000-2005	Early fixed-dose adoption	Initial product expansion
2006-2010	Competition from once-daily and newer combinations	Growth slows
2011-2015	Generic entry and integrase displacement	Brand erosion accelerates
2016-2020	Mature decline	Low strategic priority
2021-2024	Generic, tender and residual-use market	Limited revenue contribution

The largest value migration occurred from older NRTI combinations into newer integrase inhibitor products. Within the ViiV portfolio, commercial emphasis shifted toward Tivicay, Triumeq, Juluca and long-acting Cabenuva, while Trizivir became a legacy product.

Revenue exposure remains relevant in three areas:

• Institutional and government procurement.
• Markets where low-cost generic supply is prioritized.
• Patients who cannot use tenofovir-based regimens or newer alternatives.

Those channels produce volume but weak margins. Brand maintenance, pharmacovigilance, regulatory compliance and supply-chain costs can consume a larger share of revenue as volumes decline.

What licensing deals affect the product?

The relevant commercial structure is the transfer and management of GlaxoSmithKline’s HIV business into ViiV Healthcare. ViiV was established in 2009 by GSK and Pfizer to focus on HIV medicines. Shionogi later became a shareholder.[5]

The ViiV structure affects Trizivir through portfolio ownership, regulatory maintenance and supply decisions. It does not create new patent exclusivity. Licensing and commercialization arrangements involving regional generic manufacturers may support access in low- and middle-income countries, but these agreements generally have limited impact on developed-market pricing.

What patent litigation affects abacavir, lamivudine and zidovudine?

Trizivir has no major current U.S. patent litigation that materially threatens market access or supports a branded pricing strategy. Historical disputes involving individual NRTI patents were more important during the initial development and launch periods.

The litigation profile is now characterized by:

• No meaningful live patent barrier in the United States.
• Low likelihood of high-value Paragraph IV litigation.
• No biosimilar litigation pathway.
• Potential ordinary disputes over quality, supply, trademarks or regulatory compliance.
• Greater litigation relevance for newer abacavir products, such as Triumeq, than for Trizivir itself.

What is the geographic coverage of the product?

The combination has been marketed internationally under Trizivir or local equivalents, but its commercial position varies sharply by market.

Region	Market condition
United States	Approved legacy product with generic competition
European Union	Mature market; national reimbursement and generic substitution dominate
United Kingdom	Low-cost HIV procurement and limited branded leverage
Low- and middle-income countries	Public-health tenders and generic supply are more important
Emerging markets	Access depends on registration, local manufacturing and procurement channels
Japan and other regulated markets	Product use is constrained by treatment guidelines and local reimbursement

The geographic opportunity is concentrated in price-sensitive markets, but these markets usually provide low unit economics. Volume expansion would not necessarily translate into material profit growth.

What manufacturing and intellectual-property barriers remain?

Manufacturing barriers are operational rather than patent-based. A supplier must produce a stable fixed-dose tablet containing three active ingredients with different dose levels, physicochemical properties and quality requirements.

Key barriers include:

• Consistent supply of abacavir sulfate, lamivudine and zidovudine.
• Control of blend uniformity and content uniformity.
• Validation of dissolution and bioequivalence.
• Management of zidovudine-related impurities.
• Compliance with current good manufacturing practices.
• Registration across multiple national authorities.
• Tender qualification and pharmacovigilance obligations.

These barriers can reduce the number of active suppliers, but they do not provide durable market exclusivity. A qualified manufacturer with a low-cost supply chain can enter once regulatory requirements are met.

What generic launch scenarios are most likely?

The most probable commercial scenario is continued erosion with fragmented generic supply rather than a major new launch event.

Scenario	Probability profile	Market result
Continued brand decline	High	Trizivir remains a residual product
Additional generic suppliers	Moderate to high	Lower prices and wider substitution
Public-tender revival	Moderate	Volume increase with low margins
Brand-led repositioning	Low	Limited clinical rationale
Patent-driven delay	Very low	No material live estate
Product withdrawal in selected markets	Moderate	Portfolio rationalization

A generic manufacturer can achieve modest revenue by targeting countries with established treatment protocols, local procurement systems or limited availability of newer combinations. In the United States and Western Europe, the addressable opportunity is constrained by clinical preference and generic substitution.

Key Takeaways

• Trizivir is the fixed-dose combination of abacavir sulfate, lamivudine and zidovudine.
• FDA approval dates to November 2000.
• The product is no longer a preferred first-line HIV regimen.
• Principal patent and regulatory exclusivity periods have expired.
• Paragraph IV and patent litigation risk is low.
• Biosimilar competition is irrelevant because Trizivir is a small-molecule drug.
• Generic substitution includes both the fixed-dose combination and separate active ingredients.
• ViiV Healthcare controls the branded HIV portfolio, but public filings do not separately disclose current Trizivir revenue.
• The financial trajectory is mature-to-declining, with residual demand in tenders and specialized treatment settings.
• Manufacturing and regulatory execution, rather than intellectual property, are the main barriers to entry.

FAQs about abacavir sulfate, lamivudine and zidovudine

Is Trizivir still available in the United States?

Trizivir remains an FDA-approved product, but availability and commercial distribution can vary. Generic or separate-component alternatives are more important than the branded product.

Is abacavir sulfate, lamivudine and zidovudine a generic drug?

The individual ingredients and fixed-dose combinations are available from generic manufacturers in multiple markets. Trizivir is the original branded product.

Does Trizivir have a biosimilar competitor?

No. Biosimilar regulation applies to biologic products. Trizivir is a conventional small-molecule tablet and competes through generic-drug pathways.

Why has Trizivir lost market share?

The product is twice daily, contains zidovudine, requires abacavir-related HLA-B*5701 screening and has been displaced by once-daily integrase inhibitor regimens with stronger resistance profiles and better guideline positioning.

Is Trizivir commercially attractive for a generic manufacturer?

The product may offer a niche opportunity in public tenders and selected emerging markets. Its commercial attractiveness is limited by low pricing, broad competition, mature demand and substitution by other antiretroviral combinations.

References

1. U.S. Food and Drug Administration. (2023). Trizivir prescribing information.
2. Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. U.S. Department of Health and Human Services.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. GSK plc. (2024). Annual report 2023.
5. ViiV Healthcare. (2024). Company overview and HIV medicines portfolio.